Bicycle Therapeutics plc (50BA.F)

Compare

11.90

-0.20

(-1.65%)

At close: January 31 at 3:29:01 PM GMT+1

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

CAMBRIDGE, England & BOSTON, January 13, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and

Business Wire 19 days ago

BCYC
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, England & BOSTON, January 09, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT.

Business Wire 23 days ago

BCYC
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON, January 03, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the company’s Board of Directors granted to 12 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 67,300 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i

Business Wire 28 days ago

BCYC
First Solar, Frontier Communications, and More Stocks See Action From Activist Investors

Activists report to the SEC on First Solar, Bicycle Therapeutics, Garrett Motion, Frontier Communications, nCino, and Ormat Technologies

Barrons.com last month

ORA

NCNO

GTX
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

On Thursday, Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium. The company revealed topline combination data for zelenectide pevedotin plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial ca

Benzinga last month

BCYC
We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. last month

BCYC
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

CAMBRIDGE, England & BOSTON, December 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The

Business Wire last month

BCYC
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

CAMBRIDGE, England & BOSTON, December 10, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company’s clinical oncology programs.

Business Wire last month

BCYC
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

CAMBRIDGE, England & BOSTON, November 25, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABC

Business Wire 2 months ago

BCYC
Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index […]

Insider Monkey 2 months ago

BCYC
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, England & BOSTON, November 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT.

Business Wire 2 months ago

BCYC
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics ( NASDAQ:BCYC ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.68m (down 50% from...

Simply Wall St. 2 months ago

BCYC
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

CAMBRIDGE, England & BOSTON, October 31, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the third quarter ended September 30, 2024.

Business Wire 3 months ago

BCYC
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

CAMBRIDGE, England & BOSTON, October 23, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrating the positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use, as we

Business Wire 3 months ago

BCYC
Bicycle Therapeutics (BCYC): High-Growth UK Stock with Innovative Peptide Technology

We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where Bicycle Therapeutics (NASDAQ:BCYC) stands against other high growth UK stocks to invest in. According to a KPMG report, the United Kingdom’s GDP growth is projected to slow in the […]

Insider Monkey 3 months ago

BCYC
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

CAMBRIDGE, England & BOSTON, October 16, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place

Business Wire 3 months ago

BCYC
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?

Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 3 months ago

BCYC

VYGR
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

BARCELONA, September 14, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agoni

Business Wire 4 months ago

BCYC
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

RBC Capital initiated coverage on Bicycle Therapeutics PLC (NASDAQ:BCYC), noting an advantage in oncology and beyond. The analyst writes the company’s lead program, Zelenectide pevedotin (zele, formerly BT8009), shows potential to compete in metastatic urothelial cancer (mUC) due to similar objective response rates and fewer adverse events compared to Pfizer Inc’s (NYSE:PFE) Seagen Inc. drug, Padcev. The improved safety profile of Zelenectide could result in greater antitumor durability, a key d

Benzinga 4 months ago

BCYC
Bicycle Therapeutics (NASDAQ:BCYC) shareholders have earned a 26% CAGR over the last five years

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Simply Wall St. 5 months ago

BCYC

Performance Overview

Return	50BA.F	MSCI WORLD
YTD	-10.53%	+3.16%
1-Year	-25.63%	+19.69%
3-Year	-70.54%	+25.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bicycle Therapeutics plc (50BA.F)

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

First Solar, Frontier Communications, and More Stocks See Action From Activist Investors

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Bicycle Therapeutics (BCYC): High-Growth UK Stock with Innovative Peptide Technology

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

Bicycle Therapeutics (NASDAQ:BCYC) shareholders have earned a 26% CAGR over the last five years

Performance Overview